Table 1

Baseline sociodemographic and behavioural characteristics of patients included and excluded from analysis of the NABOGO trial, Amsterdam, the Netherlands, from 18 September 2017 to 5 June 2020

	Included in the analysis (n=241)*		Excluded from the analysis (n=105)*		P value†
	n*	%*	n*	%*	P value†
Demographics
Age (years)					0.582
Median (IQR)	32	(26–41)	35	(27–42)
<30	99	41.10	37	35.20
30–39	73	30.30	34	32.40
≥40	69	28.60	34	32.40
Gender identity					0.003
Male	223	92.50	105	100
Female	17	7.10	0	0.00
Transgender	1	0.40	0	0.00
Ethnicity					0.514
Dutch	158	65.60	65	61.90
Non-Dutch	83	34.40	40	38.10
Highest education level					0.040
None/primary/secondary	48	20.10	31	29.50
College/university	172	72.00	61	58.10
Other	19	8.00	13	12.40
Health
Antibiotic use‡					0.934
No	171	85.50	85	85.90
Yes	29	14.50	14	14.10
Coinfection with chlamydia					<0.001
No	232	96.30	83	79.10
Yes	9	3.70	22	21.00
Sexual behaviour
Sexual risk group					<0.001
MSM	221	91.70	91	87.50
MSW	2	0.80	13	12.50
Women	17	7.10	0	0.00
TGP	1	0.40	0	0.00
Number of sexual partners§
Median (IQR)	10	(5–20)	6	(3–15)	0.018
HIV characteristics
HIV status					0.128
Negative	194	81.50	78	74.30
Positive	44	18.50	27	25.70
cART use¶					0.55
No	1	2.30	2	8.00
Yes	42	97.70	23	92.00
Most recent CD4 cell count (cells/µL)¶					0.517
<350	0	0.00	1	5.00
350–499	4	12.10	3	15.00
≥500	29	87.90	16	80.00
PrEP use**					0.005
No	123	63.40	63	80.80
Yes	71	36.60	15	19.20

Data on the number of sexual partners were from the initial consultation, which is the T₋₁ visit, for all asymptomatic patients. All other data on sociodemographic, behavioural and HIV characteristics were from the T₀ visit.
Data were missing (n=included/n=excluded) for education level (n=2/n=0), antibiotic use (n=41/n=6), sexual risk group (n=0/n=1), number of sexual partners (n=1/n=4), HIV status (n=3/n=0), cART use (n=1/n=2) and CD4 cell count (n=11/n=7).
Not all participants were tested at all anatomical sites; testing depended on own gender and gender of sexual partners. Number of NAATs not tested for anal (n=11), pharyngeal (n=13), vaginal (n=224) and urethral (n=18) samples.
*Unless otherwise stated.
†P values were calculated using χ² test or Fisher’s exact test (for categorical data) and Student’s t-test or Wilcoxon rank-sum test (for continuous data).
‡In the preceding 3 months before the initial consultation.
§In the preceding 6 months before the initial consultation.
¶Among participants living with HIV.
**Among HIV-negative participants. All patients who used PrEP were MSM.
cART, combination antiretroviral therapy; MSM, men who have sex with men; MSW, men who have exclusively sex with women; NAAT, nucleic acid amplification test; NABOGO, New AntiBiotic treatment Options for uncomplicated GOnorrhoea; PrEP, pre-exposure prophylaxis; TGP, transgender people.